Connor, Clark & Lunn Investment Management (CC&L)
APGE

Connor, Clark & Lunn Investment Management (CC&L)’s Apogee Therapeutics APGE Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$243K Sell
1,834
-9,647
-84% -$869K ﹤0.01% 1531
2026
Q1 		$966K Sell
11,481
-1,208
-10% -$87.7K ﹤0.01% 1167
2025
Q4 		$958K Buy
+12,689
New +$799K ﹤0.01% 1145

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s APGE Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Apogee Therapeutics (APGE) stake by 84% in Q2 2026, selling an estimated $869K and leaving 1,834 shares worth $243K. The position accounts for ﹤0.01% of the portfolio, ranked #1531.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in APGE in Q4 2025 and has held it in 3 quarters since. The position peaked at $966K in Q1 2026. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 1,834 shares of Apogee Therapeutics worth $243K as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 9,647 Apogee Therapeutics shares in Q2 2026, an estimated $869K.
  • Apogee Therapeutics made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #1531 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Apogee Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Apogee Therapeutics position peaked at $966K in Q1 2026.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.